<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Islet amyloid is a characteristic feature of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Its major component is the <z:mpath ids='MPATH_458'>normal</z:mpath> beta-cell secretory product amylin, or islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (IAPP) </plain></SENT>
<SENT sid="2" pm="."><plain>To determine whether increased or disproportionate release of amylin may explain the propensity for <z:mpath ids='MPATH_34'>amyloid deposition</z:mpath> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we measured plasma amylin-like immunoreactivity (ALI) and immunoreactive insulin (IRI) release in response to an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> load in 94 Japanese-American subjects with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (NGT; n=56), <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT; n=10), and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n=28) as defined by World Health Organization criteria </plain></SENT>
<SENT sid="3" pm="."><plain>The incremental increase in ALI, IRI, and <z:chebi fb="105" ids="17234">glucose</z:chebi> (G) at 30 min after oral <z:chebi fb="105" ids="17234">glucose</z:chebi> ingestion was used to calculate deltaALI/deltaG and deltaIRI/deltaG as measures of beta-cell function </plain></SENT>
<SENT sid="4" pm="."><plain>Overall <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism was assessed as the incremental <z:chebi fb="105" ids="17234">glucose</z:chebi> area (<z:chebi fb="105" ids="17234">glucose</z:chebi> AUC) during the 2 h of the oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test </plain></SENT>
<SENT sid="5" pm="."><plain>As expected, plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations at both fasting (NGT, 5.0+/-0.4; IGT, 5.5+/-0.1; type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 6.2+/-0.3 mmol/l; P &lt; 0.0001) and 2 h (NGT, 6.7+/-0.1; IGT, 9.4+/-0.3; type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 13.2 +/-0.5 mmol/l; P &lt; 0.0001) were elevated in individuals with IGT and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>In response to <z:chebi fb="105" ids="17234">glucose</z:chebi> ingestion, plasma IRI and ALI increased in <z:hpo ids='HP_0000001'>all</z:hpo> subjects, but these increments were lower in individuals with <z:mp ids='MP_0005293'>reduced glucose tolerance</z:mp>, as reflected in the deltaIRI/deltaG (NGT, 119+/-10.3; IGT, 60.7+/-7.1; type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 49.7 +/-5.4 pmol/l; P &lt; 0.0001) and deltaALI/deltaG (NGT, 2.6+/-0.2; IGT, 1.8+/-0.3; type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 1.2+/-0.1 pmol/l; P &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, these reductions in the 30-min incremental ALI and IRI responses were proportionate such that the molar ratio of ALI to IRI was not different among the three groups (NGT, 2.6+/-0.2; IGT, 2.9 +/-0.3; type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 2.9+/-0.3%; NS) </plain></SENT>
<SENT sid="8" pm="."><plain>Further, the relationship between beta-cell function, measured as either deltaIRI/deltaG or deltaALI/deltaG, and <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, assessed as <z:chebi fb="105" ids="17234">glucose</z:chebi> AUC, was nonlinear and inverse in nature, with r2 values of 0.38 (P &lt; 0.0001) and 0.33 (P &lt; 0.0001), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that the reduced beta-cell function of IGT and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> includes proportionate reductions in both IRI and ALI release </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, it is unlikely that the development of islet amyloid in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is the result of increased release of ALI </plain></SENT>
</text></document>